Cash, cash equivalents and marketable securities as of December 31, 2022, were $204.4M. Olema anticipates that this balance will be sufficient to fund operations into 2025. "2022 was a successful year for Olema as we generated important clinical data advancing the opportunity for OP-1250, our complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), as both a monotherapy and in combination with a CDK4/6 inhibitor. We continue to have confidence in OP-1250’s ability to become a best-in-class treatment option for ER+/HER2- metastatic breast cancer," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "We are committed to realizing the full potential of OP-1250, which we believe has demonstrated a clear, differentiated advantage as a complete ER antagonist and the potential endocrine therapy of choice. Given the challenging equity market environment, we made some difficult decisions regarding our organization and earlier-stage programs. As we sharpen our focus on the late-stage clinical development of OP-1250, we remain steadfast in our goal of bringing this potentially transformative therapy to women living with breast cancer."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OLMA:
- Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
- Olema Oncology initiated with an Outperform at Credit Suisse
- Olema Oncology to Participate at Upcoming Investor Conferences